BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gilotrif (Afatinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Gilotrif (Afatinib)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02491099-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gilotrif (Afatinib): Phase 2 readout est. (NCT02491099)
DESCRIPTION:Gilotrif (Afatinib)\, phase 2.\nStudy: A Phase II Evaluation of
  Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine S
 erous Carcinoma\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/afatinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02491099
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04185883-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Gilotrif (Afatinib): Phase 1 readout est. (NCT04185883)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1.\nStudy: Sotorasib Activity in Su
 bjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101
 )\nEstimated primary completion: 17 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/afatinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413201-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gilotrif (Afatinib): Phase 4 readout est. (NCT04413201)
DESCRIPTION:Gilotrif (Afatinib)\, phase 4\, Non-Small Cell Lung Cancer.\nSt
 udy: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Comp
 ared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative N
 onsquamous NSCLC\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/afatinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04413201
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05070403-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Gilotrif (Afatinib): Phase 2 readout est. (NCT05070403)
DESCRIPTION:Gilotrif (Afatinib)\, phase 2.\nStudy: Study of Afatinib in Adv
 anced Cutaneous Squamous Cell Carcinoma\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/afatinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0507
 0403
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010120-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Gilotrif (Afatinib): Phase 1/2 readout est. (NCT07010120)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1/2.\nStudy: A Clinical Trial of Ne
 oadjuvant Targeted Therapy\, Immunotherapy\, and Lysogenic HSV-Based Virot
 herapy in Resectable Head and Neck Squamous Cell Carcinoma\nEstimated prim
 ary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/afatinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07010120
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05432518-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Gilotrif (Afatinib): Phase 1 readout est. (NCT05432518)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1.\nStudy: Pilot Trial for Treatmen
 t of Recurrent Glioblastoma\nEstimated primary completion: 1 July 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/afatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05432518
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06753747-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gilotrif (Afatinib): Phase 1/2 readout est. (NCT06753747)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1/2.\nStudy: A Trial of the Combina
 tion of Afatinib and Palbociclib in Previously Treated Advanced Esophageal
  Squamous Cell Carcinoma\nEstimated primary completion: September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/afatinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06753747
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Gilotrif (Afatinib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Gilotrif (Afatinib)\, phase 2.\nStudy: The Drug Rediscovery Pro
 tocol (DRUP Trial)\nEstimated primary completion: September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/afatinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06302621-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Gilotrif (Afatinib): Phase 1 readout est. (NCT06302621)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1.\nStudy: Pemigatinib + Afatinib i
 n Advanced Refractory Solid Tumors\nEstimated primary completion: 1 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/afatinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0630262
 1
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085755-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Gilotrif (Afatinib): Phase 1/2 readout est. (NCT06085755)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1/2.\nStudy: Trastuzumab Deruxtecan
 (T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer\nEsti
 mated primary completion: 1 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/afatinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06085755
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gilotrif (Afatinib): Phase 2 readout est. (NCT02465060)
DESCRIPTION:Gilotrif (Afatinib)\, phase 2.\nStudy: Targeted Therapy Directe
 d by Genetic Testing in Treating Patients With Advanced Refractory Solid T
 umors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/afatinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653451-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Gilotrif (Afatinib): Phase 2/3 readout est. (NCT07653451)
DESCRIPTION:Gilotrif (Afatinib)\, phase 2/3.\nStudy: Precision Medicine for
  Immunotherapy-Resistant Advanced Esophageal Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/afatinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07653451
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486142-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Gilotrif (Afatinib): Phase 3 readout est. (NCT06486142)
DESCRIPTION:Gilotrif (Afatinib)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study\n
 Estimated primary completion: September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06486142
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06648096-1976@assetmemo.bio
DTSTAMP:20261121T004049Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Gilotrif (Afatinib): Phase 1/2 readout est. (NCT06648096)
DESCRIPTION:Gilotrif (Afatinib)\, phase 1/2.\nStudy: Afatinib in Patients W
 ith Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma
  (HNSCC)\nEstimated primary completion: December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/afatinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06648096
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
